CA2787919C - Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs - Google Patents

Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs Download PDF

Info

Publication number
CA2787919C
CA2787919C CA2787919A CA2787919A CA2787919C CA 2787919 C CA2787919 C CA 2787919C CA 2787919 A CA2787919 A CA 2787919A CA 2787919 A CA2787919 A CA 2787919A CA 2787919 C CA2787919 C CA 2787919C
Authority
CA
Canada
Prior art keywords
compound
formula
silyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2787919A
Other languages
English (en)
French (fr)
Other versions
CA2787919A1 (en
Inventor
Atsushi Endo
Charles E. Chase
Francis G. Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA2787919A1 publication Critical patent/CA2787919A1/en
Application granted granted Critical
Publication of CA2787919C publication Critical patent/CA2787919C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2787919A 2010-01-26 2011-01-26 Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs Active CA2787919C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29833710P 2010-01-26 2010-01-26
US61/298,337 2010-01-26
PCT/US2011/022611 WO2011094339A1 (en) 2010-01-26 2011-01-26 Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Publications (2)

Publication Number Publication Date
CA2787919A1 CA2787919A1 (en) 2011-08-04
CA2787919C true CA2787919C (en) 2018-07-31

Family

ID=43726543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2787919A Active CA2787919C (en) 2010-01-26 2011-01-26 Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Country Status (11)

Country Link
US (6) US8203010B2 (https=)
EP (1) EP2528914B1 (https=)
JP (1) JP5800834B2 (https=)
CN (1) CN102803254B (https=)
BR (1) BR112012018232B8 (https=)
CA (1) CA2787919C (https=)
IL (1) IL220913A (https=)
MX (1) MX2012008510A (https=)
RU (1) RU2579511C2 (https=)
SG (2) SG10201500552PA (https=)
WO (1) WO2011094339A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
GB2526955B (en) 2011-09-18 2016-06-15 Touchtunes Music Corp Digital jukebox device with karaoke and/or photo booth features, and associated methods
RU2689977C2 (ru) 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
BR112015029386B1 (pt) 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
EP3016957A4 (en) 2013-07-03 2016-11-30 Alphora Res Inc SYNTHETIC METHOD FOR THE PRODUCTION OF CYCLIC C1-KETO ANALOGUE OF HALICHONDRIN B AND USEFUL INTERMEDIATE PRODUCTS, INCLUDING INTERMEDIATE PRODUCTS WITH -SO2- (P-TOLYL) GROUPS
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
BR112016009452B1 (pt) * 2013-11-04 2022-06-07 Eisai R&D Management Co., Ltd Métodos de preparar intermediários na síntese de eribulina, métodos de preparar eribulina e mesilato de eribulina, e compostos intermediários
EP3077399B1 (en) 2013-12-06 2019-02-20 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
US20170100367A1 (en) 2014-05-28 2017-04-13 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX392296B (es) 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
CN108601760A (zh) 2016-02-12 2018-09-28 卫材R&D管理有限公司 艾日布林的合成中的中间体及相关的合成方法
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
KR102404629B1 (ko) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체
WO2018071792A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
CN108658956B (zh) * 2017-03-28 2021-02-02 上海时莱生物技术有限公司 艾日布林中间体及其制备方法
SMT202200455T1 (it) 2017-04-05 2023-01-13 Harvard College Composto macrociclico e relativi usi
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
CN108948064B (zh) * 2017-05-17 2021-02-02 上海时莱生物技术有限公司 一种艾日布林中间体及其制备方法
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019010363A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College HALICHONDRINES SYNTHESIS
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
IL275729B2 (en) 2018-01-03 2023-09-01 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of helicondrin macrolides and their analogs
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) * 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (https=) 1992-09-09 1995-09-01 Hoechst Ag
AU4255697A (en) 1996-09-06 1998-03-26 Eli Lilly And Company Catalytic selective sulfonylation process
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) * 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
US20060154312A1 (en) 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
CN101910180A (zh) * 2007-11-16 2010-12-08 卫材R&D管理有限公司 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
EP3016957A4 (en) 2013-07-03 2016-11-30 Alphora Res Inc SYNTHETIC METHOD FOR THE PRODUCTION OF CYCLIC C1-KETO ANALOGUE OF HALICHONDRIN B AND USEFUL INTERMEDIATE PRODUCTS, INCLUDING INTERMEDIATE PRODUCTS WITH -SO2- (P-TOLYL) GROUPS
BR112016009452B1 (pt) 2013-11-04 2022-06-07 Eisai R&D Management Co., Ltd Métodos de preparar intermediários na síntese de eribulina, métodos de preparar eribulina e mesilato de eribulina, e compostos intermediários
EP3077399B1 (en) 2013-12-06 2019-02-20 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
MX392296B (es) 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
CN108601760A (zh) 2016-02-12 2018-09-28 卫材R&D管理有限公司 艾日布林的合成中的中间体及相关的合成方法
KR102404629B1 (ko) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체

Also Published As

Publication number Publication date
CN102803254B (zh) 2016-09-14
BR112012018232A2 (pt) 2016-02-23
SG10201500552PA (en) 2015-03-30
US20130123519A1 (en) 2013-05-16
US9856276B2 (en) 2018-01-02
RU2579511C2 (ru) 2016-04-10
BR112012018232B8 (pt) 2023-01-10
US10494388B2 (en) 2019-12-03
IL220913A (en) 2016-11-30
US20150175620A1 (en) 2015-06-25
MX2012008510A (es) 2012-11-21
US8203010B2 (en) 2012-06-19
CA2787919A1 (en) 2011-08-04
CN102803254A (zh) 2012-11-28
US8927597B2 (en) 2015-01-06
JP2013518116A (ja) 2013-05-20
EP2528914A1 (en) 2012-12-05
SG182612A1 (en) 2012-08-30
US20110184190A1 (en) 2011-07-28
EP2528914B1 (en) 2014-06-11
US8350067B2 (en) 2013-01-08
RU2012136468A (ru) 2014-03-10
BR112012018232B1 (pt) 2022-11-29
US20120289718A1 (en) 2012-11-15
US9382262B2 (en) 2016-07-05
WO2011094339A1 (en) 2011-08-04
US20180162885A1 (en) 2018-06-14
JP5800834B2 (ja) 2015-10-28
US20160376294A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
CA2787919C (en) Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
CA2567984C (en) Intermediates for the preparation of analogs of halichondrin b
WO2015000070A1 (en) Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CA2822994C (en) Intermediates for the preparation of analogs of halichondrin b
KR20130040180A (ko) 피리피로펜 유도체의 제조방법
ITMI20002553A1 (it) Procedimento per la preparazione di derivati tassanici
JP5960130B2 (ja) テセタキセルおよび関連化合物ならびに対応する合成中間体の調製
ITMI20001869A1 (it) Procedimento per la preparazione di derivati della baccatina iii
JP4170799B2 (ja) 抗腫瘍活性物質エクチナサイジン743の改良合成法
Madsen et al. Synthesis of new diverse macrocycles from diol precursors
AU2015226806A1 (en) Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
Kadota et al. Convergent synthesis of the EFGH ring system of ciguatoxin CTX3C
CN103172625A (zh) 卡巴他赛的中间体化合物
CN103012330A (zh) 一种紫杉醇类抗癌药xrp6258的制备方法
CN103172654B (zh) 紫杉烷类化合物及其制备方法
WO2010055138A1 (en) New stereospecific method for the preparation of dioxa-bicyclooctane compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160119

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260309